Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch
Kidney Failure, Chronic
About this trial
This is an interventional prevention trial for Kidney Failure, Chronic focused on measuring kidney, transplantation, positive crossmatch, antibody mediated rejection, rejection, induction, therapy, trial
Eligibility Criteria
Inclusion Criteria: Adult (18 years or older) End-stage renal disease Identified to have positive lymphocytotoxic crossmatch or flow cytometric crossmatch with live donor Exclusion Criteria: Deceased donor recipients Pregnancy Active infection History of cancer within the past two years (with the exception of non-melanomatous skin cancer) History of heparin induced thrombocytopenia Medical contraindications to transplant procedure
Sites / Locations
- The Johns Hopkins University, School of Medicine
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Thymoglobulin
Daclizumab
Thymoglobulin was administered as 1.5 mg/kg prior to reperfusion followed by 6 post-operative doses on days 1 through 6.
Daclizumab was administered as 2 mg/kg prior to reperfusion followed by 1 mg/kg every other week for 8 weeks post-operatively (4 post-operative doses).